News

Articles not undergoing peer review are reaching widespread dissemination during the pandemic. What are the implications?

Researchers find most common mutations appear to have been induced by the human immune system.

A study author at Keck Medicine of USC discusses an ongoing assessment of LY-CoV555 for preventing severe COVID-19, and the overall benefit of the drug class for pandemic mitigation.

The IDSA representative discusses advances made in recent years, and how foundational guidance could be set by the FDA with input from specialists.

The former FDA commissioner weighs in on the best measures to mitigate skyrocketed new cases, and his timeline for national recovery.

OncoSec recently received an FDA IND clearance to begin a phase 1 trial.

Important finding shows convalescent plasma provides no significant benefit in severe COVID-19 cases.

Recent study shows COVID-19 survivors health improves with support of Home Health Care.

An artificial intelligence (AI) algorithm predicts outcomes in patients diagnosed with COVID-19.

A recently created therapy for the influenza virus may help aid in the fight against COVID-19.

The guidelines were recently updated to reflect new information on COVID-19 treatment and management.

The influenza therapy is expanded to include people who have been exposed to the flu.

Accuracy of test may be influenced by size of population to be screened and prevalence of COVID-19 within that population.

New details of SARS-CoV-2 have been obtained using 3D modeling, providing crucial insights into the disease.

National Institute of Allergy and Infectious Disease (NIAID) has selected Metabolon to participate in a study on this subject.

Data shows their AZD1222 vaccine met its endpoint and they are preparing regulatory submission for conditional or early approval.

A research team developed an algorithm review estimating not only hospital admissions, but also mortality outcomes in adults with COVID-19.

Children who were exposed to antibiotics before age 2 had a greater risk of childhood health conditions like asthma, celiac disease, obesity and ADHD, a new study in Mayo Clinic Proceedings found.

Study finds that a century-old tuberculosis vaccine could be used in the treatment and prevention of COVID-19.

The third EUA granted to an investigational COVID-19 therapy regimen is indicated for preventing progression from mild, to severe symptoms.

Immunologists have discovered possible treatments for COVID-19 using existing therapies.

The Aptima HIV-1 Quant Dx assay is the first in the US to be able to make such a claim.

This guidance comes less than 24 hours after FDA grants an EUA for its use combined with baricitinib.

The measles-mumps-rubella (MMR) vaccine could potentially aid in the protection against COVID-19.

Two recent studies conducted by Kansas State University researchers resulted in important findings related to the current COVID-19 pandemic.

Here is what you need to know about BNT162b2, possibly the first vaccine regulated for COVID-19 prevention.

This EUA is for the treatment of hospitalized patients who require oxygen.